<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> associated protein 1 (MTA1) has been widely linked to <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e>, the relevant mechanisms remain to be elucidated, especially in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we have investigated the link between MTA1, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and epithelial-mesenchymal transition (EMT) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Eighteen <z:mpath ids='MPATH_458'>normal</z:mpath> colon tissues and 91 resected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples were analyzed for MTA1 expression by immunohistochemistry (IHC) </plain></SENT>
<SENT sid="3" pm="."><plain>IHC indicated low or no nuclear MTA1 expression in the <z:mpath ids='MPATH_458'>normal</z:mpath> tissues and significantly higher expression in Grade II, Grade III and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>No statistically significant difference was observed in MTA1 expression between Grade III and liver <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>To demonstrate the functional importance of MTA1 in vitro, the gene was silenced in HCT-116 cells and LoVo cells and overexpressed in HCT-116 cells </plain></SENT>
<SENT sid="6" pm="."><plain>MTA1 overexpression in HCT-116 cells enhanced proliferation, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to fibronectin, motility, migration, invasion through Matrigel, anchorage-independent growth, neoangiogenesis and induced a loss of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Silencing of MTA1 resulted in a reversal of <z:hpo ids='HP_0000001'>all</z:hpo> of these features </plain></SENT>
<SENT sid="8" pm="."><plain>Mechanistically, MTA1 silencing caused an increase in the epithelial markers E-cadherin and ZO-1 and a decrease in the mesenchymal marker vimentin while MTA1 overexpression caused an increase in vimentin expression </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, MTA1 enhanced the expression of Snai1 and Slug; silencing of MTA1 reduced their recruitment to the promoter of E-cadherin, thereby leading to its expression </plain></SENT>
<SENT sid="10" pm="."><plain>MTA1 is highly expressed in higher grade <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and is important in the orchestration of various phenotypic changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, most likely by inducing EMT </plain></SENT>
<SENT sid="11" pm="."><plain>This further corroborates its role as a master regulator in <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
</text></document>